Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naive breast cancer: real-life practice outcomes

Basit Öğe Kaydı
dc.contributor.authorEsin, Ece
dc.contributor.authorOksuzoglu, B.
dc.contributor.authorBilici, A.
dc.contributor.authorCicin, I.
dc.contributor.authorKostek, O.
dc.contributor.authorKaplan, M. A.
dc.contributor.authorAksoy, S.
dc.date.accessioned2024-04-24T16:00:02Z
dc.date.available2024-04-24T16:00:02Z
dc.date.issued2019
dc.departmentDicle Üniversitesien_US
dc.description.abstractPurposeIn this study, we aimed to describe the real-life practice outcomes of pertuzumab-trastuzumab-taxane (PTT) combination in visceral organ metastatic, trastuzumab-naive breast cancer (BC) patients.MethodsThis study was conducted by Turkish Oncology Group and included 317 patients' data from 36 centers.ResultsMedian age was 51 (22-82). Median PFS was 28.5months, while median OS was 40.3months. Patients with brain metastases (n: 13, 4.1%) had worse PFS (16.8m vs. 28.5m; p=0.002) and OS (26.7m vs. 40.3m; p=0.009). Patients older than 65years of age (n: 42, 13.2%) had significantly lower OS results (19.8m vs. 40.3m; p=0.01). Two hundred sixty-eight patients (86.7%) received docetaxel while 37 patients (11.7%) received paclitaxel. PFS and OS were similar between taxane groups. In eight patients (2.5%), 5-40% ejection fraction decrement from baseline was detected without any clinical sign of heart failure.ConclusionsOur RLP trial included only visceral metastatic, trastuzumab-naive BC patients including cases with brain involvement who received PTT combination in the first-line treatment. Regardless of negative prognostic characteristics, our results are in parallel with pivotal trial. Further strategies for brain metastasis should be developed to improve outcomes despite encouraging results with PTT treatment. Taxane selection can be personalized and endocrine maintenance may further improve outcomes after taxanes were discontinued. To our knowledge, this is the largest scale real-life clinical practice study of pertuzumab-trastuzumab-taxane therapy to date.en_US
dc.identifier.doi10.1007/s00280-018-3712-7
dc.identifier.endpage143en_US
dc.identifier.issn0344-5704
dc.identifier.issn1432-0843
dc.identifier.issue1en_US
dc.identifier.pmid30377778
dc.identifier.scopus2-s2.0-85056003618
dc.identifier.scopusqualityQ2
dc.identifier.startpage131en_US
dc.identifier.urihttps://doi.org/10.1007/s00280-018-3712-7
dc.identifier.urihttps://hdl.handle.net/11468/14350
dc.identifier.volume83en_US
dc.identifier.wosWOS:000458407200014
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofCancer Chemotherapy and Pharmacology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPertuzumaben_US
dc.subjectTrastuzumaben_US
dc.subjectAntiher2en_US
dc.subjectVisceral Metastasisen_US
dc.subjectBrain Metastasisen_US
dc.titlePertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naive breast cancer: real-life practice outcomesen_US
dc.titlePertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naive breast cancer: real-life practice outcomes
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu